ENTA in the 13F filings
Enanta Pharmaceuticals Inc · CUSIP 29251M106
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 23
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 11,090,042
- combined, among listed positions
- Reported value
- $175m
- combined, at the quarter end
Among the 92 comparable managers: 18 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,133,886.
Managers listing ENTA in Q4 2025
23 of 23 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 3,729,659 shares now+1,782,745
- Farallon Capital Management LLCexisting position · 2,772,262 shares now+650,000
- Two Sigma Investments LPexisting position · 285,448 shares now+224,726
- Invesco Ltdexisting position · 253,811 shares now+194,113
- Renaissance Technologies LLCexisting position · 642,200 shares now+162,600
Reductions
- Millennium Management LLCexisting position · 670,428 shares now-277,656
- Susquehanna International Group LLPexisting position · 10,467 shares now-106,837
- D. E. Shaw & Co.existing position · 167,714 shares now-58,030
- PDT Partners LLCexisting position · 69,197 shares now-16,825
New positions and exits
New (5)
Exited (2)
- Jane Street Group LLCwas $229k
- Tudor Investment Corpwas $125k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2014 | 2 | $13m | n.a. | n.a. |
| Q4 2014 | 1 | $9.9m | n.a. | n.a. |
| Q1 2015 | 2 | $8.3m | n.a. | n.a. |
| Q2 2015 | 1 | $12m | n.a. | n.a. |
| Q3 2015 | 1 | $27m | n.a. | n.a. |
| Q4 2015 | 1 | $27m | n.a. | n.a. |
| Q1 2016 | 2 | $24m | n.a. | n.a. |
| Q2 2016 | 2 | $16m | n.a. | n.a. |
| Q3 2016 | 2 | $10m | n.a. | n.a. |
| Q4 2016 | 1 | $19m | n.a. | n.a. |
| Q1 2017 | 2 | $8.4m | n.a. | n.a. |
| Q3 2017 | 2 | $20m | n.a. | n.a. |
| Q4 2017 | 2 | $100m | n.a. | n.a. |
| Q1 2018 | 7 | $184m | n.a. | n.a. |
| Q2 2018 | 7 | $291m | n.a. | n.a. |
| Q3 2018 | 5 | $186m | n.a. | n.a. |
| Q4 2018 | 6 | $159m | n.a. | n.a. |
| Q1 2019 | 6 | $287m | n.a. | n.a. |
| Q2 2019 | 4 | $208m | n.a. | n.a. |
| Q3 2019 | 5 | $126m | n.a. | n.a. |
| Q4 2019 | 7 | $174m | n.a. | n.a. |
| Q1 2020 | 9 | $191m | n.a. | n.a. |
| Q2 2020 | 8 | $178m | n.a. | n.a. |
| Q3 2020 | 6 | $163m | n.a. | n.a. |
| Q4 2020 | 6 | $144m | n.a. | n.a. |
| Q1 2021 | 6 | $170m | n.a. | n.a. |
| Q2 2021 | 5 | $143m | n.a. | n.a. |
| Q3 2021 | 4 | $171m | n.a. | n.a. |
| Q4 2021 | 4 | $183m | n.a. | n.a. |
| Q1 2022 | 5 | $163m | n.a. | n.a. |
| Q2 2022 | 3 | $74m | n.a. | n.a. |
| Q3 2022 | 2 | $80m | n.a. | n.a. |
| Q4 2022 | 2 | $72m | n.a. | n.a. |
| Q1 2023 | 2 | $63m | n.a. | n.a. |
| Q2 2023 | 2 | $41m | n.a. | n.a. |
| Q3 2023 | 4 | $28m | n.a. | n.a. |
| Q4 2023 | 3 | $28m | 2 | 2 |
| Q1 2024 | 3 | $52m | 2 | 1 |
| Q2 2024 | 3 | $39m | 0 | 2 |
| Q3 2024 | 2 | $31m | 1 | 0 |
| Q4 2024 | 1 | $12m | 0 | 0 |
| Q1 2025 | 2 | $12m | 2 | 0 |
| Q2 2025 | 2 | $17m | 0 | 1 |
| Q3 2025 | 3 | $37m | 0 | 1 |
| Q4 2025 | 4 | $118m | 18 | 6 |
| Q1 2026 | 2 | $84m | 11 | 11 |
| Q2 2026 | 3 | $104m | 7 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ENTA and LLY →ENTA and JNJ →ENTA and VRTX →Choose a stock to compare with ENTA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ENTA, latest filings →Back to the 13F Explorer →